Humacyte director granted 80,000 stock options
Humacyte, Inc. director Michael T. Constantino received a grant of stock options covering 80,000 shares of Common Stock.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
Humacyte, Inc. director Michael T. Constantino received a grant of stock options covering 80,000 shares of Common Stock. The options have an exercise price of $1.08 per share and expire on June 11, 2036. The first 25% vests on June 11, 2027, with the remaining portion vesting in equal monthly installments through June 11, 2030.
Insider Trade Summary
Grant/Award: 80,000 shares
Grant/Award
1 txn
Insider
Constantino Michael T.
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Options (right to buy) | 80,000 | $0.00 | $0.00 |
Holdings After Transaction:
Stock Options (right to buy) — 80,000 contracts (Direct)
Footnotes (1)
- F1. The first 25% of the option becomes exercisable on June 11, 2027, after which 1/48 of the option will become exercisable on the 11th of each month through June 11, 2030.
Key Figures
Options granted: 80,000 options
Exercise price: $1.08 per share
Expiration date: June 11, 2036
+3 more
6 metrics
Options granted
80,000 options
Stock Options (right to buy) granted to director
Exercise price
$1.08 per share
Conversion or exercise price of options
Expiration date
June 11, 2036
Option expiration for this grant
Initial vesting date
June 11, 2027
First 25% of options become exercisable
Final vesting date
June 11, 2030
Monthly vesting completes by this date
Shares underlying options
80,000 shares
Underlying Humacyte Common Stock
Key Terms
Stock Options (right to buy), Grant, award, or other acquisition, exercise price, Common Stock, +1 more
5 terms
Stock Options (right to buy) financial
"security_title: "Stock Options (right to buy)""
Grant, award, or other acquisition financial
"transaction_code_description: "Grant, award, or other acquisition""
exercise price financial
"conversion_or_exercise_price: "1.0800""
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
Common Stock financial
"underlying_security_title: "Common Stock""
Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.
derivative securities financial
"derivativeTransactionCount for derivative-type records"
Financial contracts whose value is tied to the price or performance of another asset, such as a stock, bond, commodity, index, or currency; examples include options, futures and swaps. They matter to investors because they let you protect against price swings, bet on future moves or gain larger exposure with less upfront cash—like using a lever or insurance policy on an investment—so they can amplify gains and losses and help manage portfolio risk.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transaction did Humacyte (HUMA) report in this Form 4?
Humacyte reported that director Michael T. Constantino received a grant of stock options for 80,000 shares of Common Stock. These options were awarded at an exercise price of $1.08 per share and represent a compensation-related acquisition, not an open-market share purchase or sale.
What are the key terms of Michael T. Constantino’s Humacyte (HUMA) stock options?
The grant covers 80,000 stock options with an exercise price of $1.08 per share, expiring on June 11, 2036. These options give the right to buy Humacyte Common Stock in the future, subject to the vesting schedule disclosed in the filing footnote.
How do the Humacyte (HUMA) options granted to Michael T. Constantino vest?
The first 25% of the options become exercisable on June 11, 2027. After that date, 1/48 of the total grant vests on the 11th of each month, continuing this pattern until full vesting is reached on June 11, 2030.
Is the Humacyte (HUMA) Form 4 transaction a stock purchase or sale?
The Form 4 reports an option grant, classified as a grant, award, or other acquisition. It does not show an open-market stock purchase or sale; instead, it reflects compensation-related stock options that may be exercised later at $1.08 per share.
How many Humacyte (HUMA) derivative securities does Michael T. Constantino hold after this grant?
After this transaction, Constantino holds 80,000 stock options as reported. These options are derivative securities tied to Humacyte Common Stock, and their exercisability is governed by the vesting schedule and expiration date disclosed in the Form 4.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Accepted by SEC EDGAR
Learn about SEC filing dates